Idexx's third-quarter results showed top-line and bottom-line year-over-year growth of 10% and 16%, respectively, supported by VetLab consumables and reference lab revenue that increased in double digits. Shares are up 20% at the time of writing.
Unlike human healthcare, pet health services and products require cash payments—thereby bypassing the reimbursement issues and pricing pressure associated with third-party payers.
International sales account for a substantial chunk of Idexx's total revenue; as the US dollar strengthens, Idexx would feel the pain on its top and bottom lines.
Metric | IDXX | ZTS | MRK |
|---|---|---|---|
Price/Earnings (Normalized) | 46.69 | 12.07 | 109.00 |
Price/Book Value | 28.59 | 9.80 | 8.06 |
Price/Sales | 11.56 | 3.53 | 5.39 |
Price/Cash Flow | 36.65 | 10.53 | 16.40 |
Metric | IDXX | ZTS | MRK |
|---|---|---|---|
Quick Ratio | 0.73 | 1.20 | 0.78 |
Current Ratio | 1.19 | 2.35 | 1.35 |
Interest Coverage | 43.68 | 13.52 | 3.33 |
Metric | IDXX | ZTS | MRK |
|---|---|---|---|
Return on Assets (Normalized) | 35.72% | 18.40% | 2.53% |
Return on Equity (Normalized) | 75.48% | 75.90% | 7.02% |
Return on Invested Capital (Normalized) | 46.76% | 23.13% | 4.79% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|&Rj%<d!g | LOCK|%s | $257B | |||
| Danaher Corp DHR | LOCK|knS@>Dq | LOCK|VN | $162B | |||
| Agilent Technologies Inc A | LOCK|$DkPpDvR | LOCK|R& | $49B | |||
| Waters Corp WAT | LOCK|t?%$>% | LOCK|r# | $45B | |||
| IQVIA Holdings Inc IQV | LOCK|Y!!Qkg | LOCK|rXZl | $45B | |||
| Mettler-Toledo International Inc MTD | LOCK|f^Z@$%$ | LOCK|@b$$ | $34B | |||
| Illumina Inc ILMN | LOCK|FG&&Ts | LOCK|Pr^$# | $32B | |||
| Labcorp Holdings Inc LH | LOCK|YQcr?xn | LOCK|>D^XZ | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|F^%G<@# | LOCK|PtLc | $28B |
United States